Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (99)
Australian Public Assessment Report (AusPAR) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (11)
2015 (8)
2014 (8)
2013 (14)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1994 (1)
1993 (3)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

225 result(s) found, displaying 41 to 50

Mundipharma Pty Ltd - Exudate-absorbent dressing, hydrophilic-gel Cancelled under Section 41GL(d) of the Act

5 September 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
Mundipharma Pty Ltd - Dressing, liquid barrier, synthetic polymer Cancelled under Section 41GL(d) of the Act

5 September 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
Mundipharma Pty Ltd - Dressing, occlusive, silicone Cancelled under Section 41GL(d) of the Act

5 September 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
Mundicare Skin Relief Powder Cancelled under Section 30(1)(c) of the Act

26 August 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
ELIGARD (Mundipharma Pty Ltd)

6 July 2022

Prescription medicine registration

Active ingredients: Leuprorelin acetate.
MS CONTIN SUSPENSION morphine sulfate pentahydrate 200mg modified release granules sachet Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MS CONTIN SUSPENSION morphine sulfate pentahydrate 100mg modified release granules sachet Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MS CONTIN SUSPENSION morphine sulfate pentahydrate 60mg modified release granules sachet Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MS CONTIN SUSPENSION morphine sulfate pentahydrate 30mg modified release granules sachet Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MS CONTIN SUSPENSION morphine sulfate pentahydrate 20mg modified release granules sachet Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Mundipharma Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.